Vidofludimus

Overview

Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor ( FXR ) . Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Dihydroorotate Dehydrogenase | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > FXR

Product Information

• Catalog No.: HY-14908
• CAS No.: 717824-30-1
• Molecular Formula: C20H18FNO4
• Molecular Weight: 355.36
• Purity: 99.14%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (7.04 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source